(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/024848 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 3/10* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2024/040020

(22) International Filing Date:
29 July 2024 (29.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/515,949 27 July 2023 (27.07.2023) US
63/590,883 17 October 2023 (17.10.2023) US

(71) Applicant: **PROVENTION BIO, INC.** [US/US]; 55 Broad Street, 2nd Floor, Red Bank, New Jersey 07701 (US).

(72) Inventors: **LEON, Francisco**; c/o Provention Bio, Inc., 55 Broad Street, 2nd Floor, Red Bank, New Jersey 07701 (US). **RAMOS, Eleanor L.**; 112 Kent Rd, Pacifica, CA 94044 (US).

(74) Agent: **LI, Z. Ying** et al.; Steptoe LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/024848 A1

(54) Title: METHODS FOR TREATING TYPE 1 DIABETES

(57) Abstract: Provided herein are methods of treating type 1 diabetes (T1D). Such methods can include administering to a subject in need thereof, at an interval of about 3 months to about 12 months, a first 12-day course of teplizumab at a total dose of more than about 9000 μg/m^2 and a second 12-day course of teplizumab at a total dose of more than about 9000 μg/m^2.